[Position paper of the Catalan Society of Gastroenterology: treatment of Genotype 1 Chronic Hepatitis C Virus with Triple Therapy]

Gastroenterol Hepatol. 2012 Nov;35(9):667-74. doi: 10.1016/j.gastrohep.2012.03.005. Epub 2012 May 3.
[Article in Spanish]
No abstract available

Publication types

  • Practice Guideline

MeSH terms

  • Antiviral Agents / administration & dosage
  • Antiviral Agents / therapeutic use*
  • Biopsy
  • Contraindications
  • Diagnostic Imaging / methods
  • Drug Therapy, Combination
  • Genotype
  • Health Services Accessibility
  • Hepacivirus / classification
  • Hepacivirus / genetics
  • Hepacivirus / isolation & purification*
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / genetics
  • Hepatitis C, Chronic / virology
  • Humans
  • Informed Consent
  • Interferon Type I / administration & dosage
  • Interferon Type I / therapeutic use*
  • Interferons
  • Interleukins / genetics
  • Liver Cirrhosis / diagnosis
  • Liver Cirrhosis / etiology
  • Liver Cirrhosis / pathology
  • Oligopeptides / administration & dosage
  • Oligopeptides / therapeutic use
  • Patient Care Team
  • Polyethylene Glycols / administration & dosage
  • Polyethylene Glycols / therapeutic use*
  • Proline / administration & dosage
  • Proline / analogs & derivatives
  • Proline / therapeutic use
  • Protease Inhibitors / administration & dosage
  • Protease Inhibitors / therapeutic use*
  • Recurrence
  • Ribavirin / administration & dosage
  • Ribavirin / therapeutic use
  • Viral Load

Substances

  • Antiviral Agents
  • interferon-lambda, human
  • Interferon Type I
  • Interleukins
  • Oligopeptides
  • Protease Inhibitors
  • Polyethylene Glycols
  • Ribavirin
  • telaprevir
  • N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
  • Interferons
  • Proline